Cover Image
Market Research Report

Investigation Report on China's Lamivudine Market, 2018-2022

Published by China Research and Intelligence Product code 334093
Published Content info 30 Pages
Delivery time: 1-2 business days
Price
Back to Top
Investigation Report on China's Lamivudine Market, 2018-2022
Published: September 12, 2018 Content info: 30 Pages
Description

At the end of 2017, there were more than 700,000 registered HIV-infected persons and AIDS patients in China. In addition, a large number of people infected with HIV and AIDS patients have not been discovered. Meanwhile, over 90 million people in China are infected with the hepatitis B virus.

Lamivudine is a major drug against the hepatitis B virus and AIDS in China. The Chinese government offers it to AIDS patients for free. Lamivudine is a nucleoside analog as well as an antiviral drug. In 1998, the FDA first approved Lamivudine as a treatment for hepatitis B. The State Food and Drug Administration (SFDA) approved the drug to be imported to China for the treatment of hepatitis B. In 1999, GlaxoSmithKline started to sell its original Lamivudine in the trade name "Heptodin" in China. More than 2 million hepatitis B patients and an unknown number of HIV-infected patients and AIDS patients are taking Heptodin in China.

By the end of 2017, more than 10 enterprises had been approved to produce Lamivudine tablets or capsules.

Lamivudine developed rapidly after it entered China. The sales volume reached CNY 307 million in 2012, declined from 2013 and fell to about CNY 159 million in 2017. The market is dominated by GlaxoSmithkline Pharmaceuticals (Suzhou) Co., Ltd., Wellcome Foundation, Anhui Biochem Bio-Pharmaceutical Co., Ltd. And Hunan Qianjin Xiangjiang Pharmaceutical Joint Stock Co., Ltd. GlaxoSmithkline Pharmaceuticals (Suzhou) Co., Ltd. Has the largest market share. Its sales value exceeded CNY 100 million in 2017, taking up a market share close to 67%.

Considering the large number of hepatitis B and AIDS patients in China, it is expected that the market size of China's Lamivudine market will continue to grow.

Topics Covered:

  • Development environment of China's Lamivudine market
  • Size of China's Lamivudine market
  • Competition pattern of China's Lamivudine market
  • Prices of Lamivudine in China
  • Driving forces and opportunities for China's Lamivudine market
  • Prospect of China's Lamivudine market from 2018 to 2022
Table of Contents
Product Code: 1809335

Table of Contents

1. Relevant Concepts of Lamivudine

  • 1.1. Indications for Lamivudine
  • 1.2. Development History of Lamivudine in China
  • 1.3. Governmental Approval of Lamivudine in China

2. Sales of Lamivudine in China, 2013-2017

  • 2.1. Sales Value
    • 2.1.1. Overall Sales Value
    • 2.1.2. Sales Value by Region
  • 2.2. Sales Volume
    • 2.2.1. Overall Sales Volume
    • 2.2.2. Sales Volume by Region
  • 2.3. Sales of Lamivudine by Dosage Form in China, 2013-2017
    • 2.3.1. Capsules
    • 2.3.2. Tablets

3. Analysis on Major Lamivudine Manufacturers in China, 2013-2017

  • 3.1. Analysis on Market Share of Major Lamivudine Manufacturers
    • 3.1.1. Market Share by Sales Value
    • 3.1.2. Market Share by Sales Volume
  • 3.2. GlaxoSmithkline Pharmaceuticals (Suzhou) Co., Ltd.
    • 3.2.1. Enterprise Profile
    • 3.2.2. Sales of GlaxoSmithkline Pharmaceuticals (Suzhou) Co., Ltd.'s Lamivudine in China
  • 3.3. Wellcome Foundation
    • 3.3.1. Enterprise Profile
    • 3.3.2. Sales of Wellcome Foundation's Lamivudine in China
  • 3.4. Anhui Biochem Bio-Pharmaceutical Co., Ltd.
  • 3.5. Hunan Qianjin Xiangjiang Pharmaceutical Joint Stock Co., Ltd.
  • 3.6. Beijing Winsunny Pharmaceutical Co., Ltd.

4. Prices of Lamivudine in China, 2017-2018

  • 4.1. GlaxoSmithkline Pharmaceuticals (Suzhou) Co., Ltd. (Heptodin)
  • 4.2. Wellcome Foundation
  • 4.3. Anhui Biochem Bio-Pharmaceutical Co., Ltd. (Yinding)
  • 4.4. Hunan Qianjin Xiangjiang Pharmaceutical Joint Stock Co., Ltd. (Jianganling)
  • 4.5. Beijing Winsunny Pharmaceutical Co., Ltd. (Winsunny Like)

5. Prospect of China's Lamivudine Market, 2018-2022

  • 5.1. Forecast on Market Size
  • 5.2. Forecast on Market Trend

Selected Charts

  • Chart Sales of Lamivudine in China, 2013-2017
  • Chart Sales Value of Lamivudine in Parts of China, 2013-2017
  • Chart Sales Volume of Lamivudine in China, 2013-2017
  • Chart Sales Volume of Lamivudine in Parts of China, 2013-2017
  • Chart Sales Value of Lamivudine Capsules in China, 2013-2017
  • Chart Sales Volume of Lamivudine Capsules in China, 2013-2017
  • Chart Sales Value of Lamivudine Tablets in China, 2013-2017
  • Chart Market Share of Top 5 Lamivudine Manufacturers by Sales Value in China, 2013-2017
  • Chart Market Share of Top 5 Lamivudine Manufacturers by Sales Volume in China, 2013-2017
  • Chart Sales Value of GlaxoSmithkline Pharmaceuticals (Suzhou) Co., Ltd.'s Lamivudine, 2013-2017
  • Chart Sales Value of Wellcome Foundation's Lamivudine, 2013-2017
  • Chart Sales Value of Beijing Winsunny Pharmaceutical Co., Ltd.'s Lamivudine, 2013-2017
  • Chart Prices of GlaxoSmithkline Pharmaceuticals (Suzhou) Co., Ltd.'s Lamivudine (Heptodin) in Parts of China, 2017-2018
  • Chart Prices of Anhui Biochem Bio-Pharmaceutical Co., Ltd.'s Lamivudine (Yinding) in Parts of China, 2017-2018
  • Chart Governmental Approval of Lamivudine in China
  • Chart Forecast on Sales Value of Lamivudine in China, 2018-2012
Back to Top